Trials / Completed
CompletedNCT03562871
IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC
An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 109 (actual)
- Sponsor
- IO Biotech · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if IO102 combined with pembrolizumab with or without chemotherapy is safe tolerable and effective in the treatment of Non-small Cell Lung Carcinoma (NSCLC). The hypothesis is that IO102 will improve the objective response rate (ORR) in patients with metastatic NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IO102 | test immunotherapy |
| BIOLOGICAL | pembrolizumab (Keytruda) | anti-PD-1 immunotherapy |
| DRUG | Carboplatin (Carboplatin Kabi) | chemotherapy |
| DRUG | Pemetrexed (Pemetrexed Alvogen) | chemotherapy |
Timeline
- Start date
- 2018-08-22
- Primary completion
- 2021-02-06
- Completion
- 2022-04-12
- First posted
- 2018-06-20
- Last updated
- 2022-04-21
Locations
13 sites across 4 countries: Germany, Netherlands, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03562871. Inclusion in this directory is not an endorsement.